# US 2004/0082876 A1 · Method and apparatus for determining the cerebral state of a patient with fast response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082876 A1
- Document ID: US20040082876A1
- Status: Published application
- Kind: A1
- Application number: 10/684,840
- Filed: 2003-10-14
- Published: 2004-04-29
- Earliest claimed: 2000-10-16
- Inventors: Hanna E. Viertio-Oja; Borje T. Rantala
- Web page: https://patentgrep.com/patent/US20040082876A1

## CPC

- A61B 5/16: Devices for psychotechnics (using teaching or educational appliances G09B1/00 - G09B7/00); Testing reaction times {; Devices for evaluating the psychological state}
- A61B 5/374: Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
- A61B 5/389: Electromyography [EMG]
- A61B 5/4821: {Determining level or depth of anaesthesia (based on movements A61B5/1106)}
- A61B 5/7203: {for noise prevention, reduction or removal}
- A61B 5/7257: {using Fourier transforms}
- A61B 5/726: {using Wavelet transforms}
- G06F 2218/08: Feature extraction
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)

## Abstract

A method and apparatus for ascertaining the cerebral state of a patient. The method/apparatus may find use in ascertaining the depth of anesthesia of the patient. In one embodiment, the entropy of the patient's EEG signal data is determined as an indication of the cerebral state. A frequency domain power spectrum quantity is obtained from the patient's EMG signal data. The latter quantity can be updated more frequently than the EEG entropy due to its higher frequency. The EEG entropy indication and the EMG power spectrum indication can be combined into a composite indicator that provides an immediate indication of changes in the cerebral state of the patient. In another embodiment, the frequency range over which the entropy of the biopotential signal from the patient is determined is broadened to encompass both EEG signal data and EMG signal data and the entropy so determined used as an indication of the patient's cerebral state.

## Claims

### Claim 1

A method for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said method comprising the steps of:
(a) obtaining EEG signal data from the patient;
(b) obtaining EMG signal data from the patient;
(c) analyzing a sample of sequential EEG signal data to obtain a first indication indicative of the cerebral state of the patient;
(d) analyzing a sample of sequential EMG signal data temporally related to the EEG signal data sample to obtain a second indication indicative of electromyographic activity in the patient; and
(e) producing a composite indication from the first and second indications obtained at steps (c) and (d) indicative of the cerebral state of the patient.

### Claim 2

A method for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said method rapidly indicating changes in such state and comprising the steps of:
(a) obtaining EEG signal data from the patient;
(b) obtaining EMG signal data from the patient, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of lower frequency;
(c) analyzing a sample of sequential EEG signal data to obtain a first indication indicative of the cerebral state of the patient, the length of a EEG signal data sample being such as to provide an cerebral state indication of desired accuracy;
(d) analyzing a sample of sequential EMG signal data temporally related to the EEG signal data sample to obtain a second indication indicative of electromyographic activity in the patient, it being possible to use a EMG signal data sample of shorter length than that of the EEG signal data sample due to the higher frequency of the EMG signal data; and
(e) producing a composite indication of the cerebral state of the patient from the first and second indications obtained at steps (c) and (d) indicative of the cerebral state of the patient, which composite indication can be updated at a repetition rate determined by the shorter sample length of the EMG signal data to rapidly indicate changes in the cerebral state of the patient.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein step (c) is further defined as obtaining a measure of the complexity of the EEG signal data as the first indication.

### Claim 4 (depends on 3)

The method according to claim 3 wherein step (c) is further defined as obtaining a measure of the entropy of the EEG signal data as the first indication.

### Claim 5 (depends on 4)

The method according to claim 4 wherein step (c) is further defined as obtaining the spectral entropy of the EEG signal data as the first indication.

### Claim 6 (depends on 4)

The method according to claim 4 wherein step (c) is further defined as obtaining the approximate entropy of the EEG signal as the first indication.

### Claim 7 (depends on 3)

The method according to claim 3 wherein step (c) is further defined as obtaining a Lempel-Ziv complexity measure of the EEG signal data as the first indication.

### Claim 8 (depends on 3)

A method according to claim 3 wherein step (c) is further defined as obtaining the first indication from fractal spectrum analysis.

### Claim 9 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein step (c) is further defined as obtaining the first indication from higher order frequency domain analysis including the bispectrum or trispectrum.

### Claim 10 (depends on 1, 2, 3)

The method according to claims 1, 2 or 3 wherein step (c) is further defined as obtaining the first indication from frequency domain power spectral analysis of the EEG signal data.

### Claim 11 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein step (c) is further defined as obtaining the first indication from a combination of analytical quantities obtained from the EEG signal data.

### Claim 12 (depends on 11)

The method according to claim 11 wherein step (c) is further defined as employing a bispectral index (BIS) of the EEG signal data as the first indication.

### Claim 13 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein prior to analyzing the samples in steps (c) and (d) the EEG and EMG signal data is subjected to spectral decomposition.

### Claim 14 (depends on 13)

The method according to claim 13 further defined as carrying out the spectral decomposition by means of a Fourier transform.

### Claim 15 (depends on 13)

The method according to claim 13 further defined as carrying out the spectral decomposition by employing a set of basis functions other than a Fourier set of functions.

### Claim 16 (depends on 15)

The method according to claim 15 further defined as carrying out the spectral decomposition by employing a set of basic functions corresponding to wavelet transformation.

### Claim 17 (depends on 1, 2, 3)

The method according to claims 1, 2 or 3 wherein step (d) is further defined as obtaining the second indication from a frequency domain power spectrum of the EMG signal data.

### Claim 18 (depends on 3)

The method according to claim 3 wherein step (d) is further defined as obtaining a measure of the complexity of the EMG signal data as the second indication.

### Claim 19 (depends on 18)

The method according to claim 18 wherein in step (d) a noise level is established below which the EMG signal data is considered to be zero.

### Claim 20 (depends on 1, 2)

The method according to claim 1 or claim 2 further defined as repeating steps (c), (d), and (e) to update the composite indication.

### Claim 21 (depends on 1, 2, 3, 4)

The method according to claims 1, 2, 3, 4, or 5 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 22 (depends on 17)

The method according to claims 17 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 23 (depends on 21)

The method according to claim 21 further defined as repeating steps (c), (d), and (e) to update the composite indication.

### Claim 24 (depends on 17)

The method according to claim 17 further defined as repeating steps (c), (d), and (e) to update the composite indication.

### Claim 25

A method for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said method comprising the steps of:
(a) obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of a lower frequency;
(b) analyzing a sample of sequential signal data over a frequency range that is sufficiently wide to include both the EEG and EMG signal data to obtain a measure of the complexity of the signal data; and
(c) providing the measure as an indication of the cerebral state of the patient.

### Claim 26

A method for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said method rapidly indicating changes in such state and comprising the steps of:
(a) obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of lower frequency;
(b) analyzing a sample of sequential signal data over a frequency range that is sufficiently wide to include both the EEG and EMG signal data to obtain a measure of the complexity of the signal data, it being possible to use a EMG signal data sample of shorter length than that of the EEG signal data sample due to the higher frequency of the EMG signal data; and
(c) providing the measure as an indication of the cerebral state of the patient, which indication can be updated at a repetition rate determined by the shorter sample length of the EMG signal data to rapidly indicate changes in the cerebral state of the patient.

### Claim 27 (depends on 25, 26)

The method according to claim 25 or claim 26 wherein step (b) is further defined as analyzing the biopotential signals over a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz.

### Claim 28 (depends on 25, 26)

The method according to claim 25 or claim 26 wherein step (b) is further defined as obtaining a measure of the entropy of the signal data.

### Claim 29 (depends on 27)

The method according to claim 27 wherein step (b) is further defined as obtaining a measure of the entropy of the signal data.

### Claim 30 (depends on 28)

The method according to claim 28 wherein step (b) is further defined as obtaining the spectral entropy of the signal data.

### Claim 31 (depends on 28)

The method according to claim 28 wherein step (b) is further defined as obtaining the approximate entropy of the signal data.

### Claim 32 (depends on 25, 26)

The method according to claim 25 or claim 26 wherein step (b) is further defined as obtaining a Lempel-Ziv complexity measure of the signal data.

### Claim 33 (depends on 25, 26)

A method according to claim 25 or claim 26 wherein step (b) is further defined as obtaining the complexity measure from fractal spectrum analysis.

### Claim 34 (depends on 25, 26)

The method according to claim 25 or claim 26 wherein prior to analyzing the sample in step (b) the biopotential signal is subjected to spectral decomposition.

### Claim 35 (depends on 34)

The method according to claim 34 further defined as carrying out the spectral decomposition by means of a Fourier transform.

### Claim 36 (depends on 34)

The method according to claim 34 further defined as carrying out the spectral decomposition by employing a set of basis functions other than a Fourier set of functions.

### Claim 37 (depends on 36)

The method according to claim 36 further defined as carrying out the spectral decomposition by employing a set of basic functions corresponding to wavelet transformation.

### Claim 38 (depends on 25, 26)

The method according to claim 25 or claim 26 further defined as repeating steps (c), (d), and (e) to update the indication.

### Claim 39 (depends on 25, 26)

The method according to claim 25 or claim 26 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 40 (depends on 27)

The method according to claim 27 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 41 (depends on 28)

The method according to claim 28 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 42 (depends on 29)

The method according to claim 29 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 43 (depends on 39)

The method according to claim 39 further defined as repeating steps (c), (d), and (e) to update the composite indication.

### Claim 44 (depends on 25, 26)

The method according to claim 25 or claim 26 further defined as including the steps of analyzing a sample of the EEG signal data to obtain a complexity measure of the EEG signal data and providing the complexity measure of the EEG signal data as a further indication of the cerebral state of the patient.

### Claim 45 (depends on 44)

The method according to claim 44 further defined as normalizing the further indication obtained from the analysis of the EEG signal data and the EEG-EMG signal data indication so that the further indication and EEG-EMG indication are equal in the absence of EMG signal data.

### Claim 46 (depends on 45)

The method according to claim 45 wherein the normalizing is carried out by multiplying the complexity measure of the EEG signal data by a quantity comprising the logarithm of the number of frequency components used for computations for the EEG signal data complexity measure divided by the logarithm of the number of frequency components used for the computations for the combined EEG-EMG complexity measure.

### Claim 47 (depends on 45)

The method according to claim 45 further defined as applying a constant to the normalized indications to maintain the normalization.

### Claim 48 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein step (a) is further defined as obtaining the EEG signal data in a frequency range of approximately 0.5-32 Hz.

### Claim 49 (depends on 1, 2)

The method according to claim 1 or claim 2 wherein step (b) is further defined as obtaining EMG signal data in a range of approximately 32-300 Hz.

### Claim 50 (depends on 49)

The method according to claim 49 further defined as notch filtering the EMG signal data to remove power line frequency harmonics.

### Claim 51 (depends on 25, 26)

The method according to claim 25 or claim 26 further defined as notch filtering to remove power line frequency harmonics.

### Claim 52 (depends on 1, 2, 25)

The method according to claim 1, 2, 25, or 26 wherein the EEG signal data and the EMG signal data are obtained from a common signal source.

### Claim 53 (depends on 52)

The method according to claim 52 wherein the EEG and EMG signal data are obtained from biopotential electrodes applied to the head of the patient.

### Claim 54 (depends on 53)

The method according to claim 53 wherein at least the EMG signal data is obtained from electrodes applied to the forehead of the patient.

### Claim 55 (depends on 1, 2)

The method according to claim 1 or claim 2 further defined as processing the EEG and EMG signal data to detect artifacts.

### Claim 56 (depends on 25, 26)

The method according to claim 25 or 26 further defined as processing the biopotential signals or signal data to detect artifacts.

### Claim 57 (depends on 55)

The method according to claim 55 further defined as filtering the signal data to remove artifacts.

### Claim 58 (depends on 56)

The method according to claim 56 further defined as filtering the signal data or biopotential signals to remove artifacts.

### Claim 59 (depends on 55)

The method according to claim 55 further defined as preventing the use of signal data affected by artifacts.

### Claim 60 (depends on 56)

The method according to claim 56 further defined as preventing the use of signal data or biopotential signals affected by artifacts.

### Claim 61 (depends on 55)

The method according to claim 55 further defined as detecting excessive muscle activity in the patient from the EMG signal data and preventing the use of EEG signal data affected by the muscle activity.

### Claim 62 (depends on 56)

The method according to claim 56 further defined as detecting excessive muscle activity in the patient from the biopotential signals or signal data and preventing the use of EEG signal data affected by the muscle activity.

### Claim 63 (depends on 55)

The method according to claim 55 further defined as including the step of sensing the presence of electrical energy at electro surgical frequencies and as preventing the use of signal data affected by such an artifact.

### Claim 64 (depends on 56)

The method according to claim 56 further defined as including the step of sensing the presence of electrical energy at electro surgical frequencies and as preventing the use of biopotential signals or signal data affected by such an artifact.

### Claim 65 (depends on 55)

The method according to claim 55 further defined as detecting simultaneous spikes in both the EEG signal data and EMG signal data as eye movement artifacts and preventing the use of signal data affected by such artifacts.

### Claim 66 (depends on 56)

The method according to claim 56 further defined as detecting simultaneous spikes in both the EEG signal data and EMG signal data as eye movement artifacts and preventing the use of biopotential signals or signal data affected by such artifacts.

### Claim 67

A method for ascertaining the depth of anesthesia of a patient, said method rapidly indicating changes in the hypnotic state of the patient and comprising the steps of:
(a) obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of lower frequency;
(b) analyzing a sample of sequential signal data existing in a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz to obtain a measure of the complexity of the signal data, it being possible to use a EMG signal data sample of shorter length than that of the EEG signal data sample due to the higher frequency of the EMG signal data;
(c) providing the complexity measure as a first indication of the cerebral state of the patient, which indication can be updated at a repetition rate determined by the shorter sample length of the EMG signal data to rapidly indicate changes in the cerebral state of the patient;
(d) analyzing a sample of EEG signal data to obtain a complexity measure of the EEG signal data;
(e) providing the complexity measure of the EEG signal data as a second indication of the cerebral state of the patient; and
(f) normalizing the first indication and second indication so that the first indication and second indication are equal in the absence of EMG signal data.

### Claim 68

Apparatus for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said apparatus comprising:
(a) means for obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data;
(b) means analyzing a sample of sequential EEG signal data to obtain a first indicator indicative of the cerebral state of the patient and analyzing a sample of sequential EMG signal data temporally related to the EEG signal data sample to obtain a second indicator indicative of electromyographic activity in the patient; and
(c) means producing a composite indicator from the first and second indicators indicative of the cerebral state of the patient.

### Claim 69 (depends on 68)

The apparatus according to claim 68 wherein said analyzing means is further defined as using a length of an EEG signal data sample to determine the first indicator and using an EMG signal data sample of shorter length than the EEG signal data sample to determine said second indicator, said analyzing means completely updating said second indicator more frequently than said first indicator.

### Claim 70 (depends on 68, 69)

The apparatus according to claim 68 or claim 69 wherein said analyzing means is further defined as obtaining a measure of the complexity of the EEG signal data as the first indicator.

### Claim 71 (depends on 70)

The apparatus according to claim 70 wherein said analyzing means is further defined as obtaining a measure of the entropy of the EEG signal data as the first indicator.

### Claim 72 (depends on 70)

The apparatus according to claim 70 wherein said analyzing means is further defined as obtaining a Lempel-Ziv complexity measure of the EEG signal data as the first indicator.

### Claim 73 (depends on 68, 69)

The apparatus according to claims 68, 69, or 70 wherein said analyzing means is further defined as obtaining the second indication from a frequency domain power spectrum of the EMG signal data.

### Claim 74 (depends on 68, 69, 70)

The apparatus according to claims 68, 69, 70, or 71 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 75

Apparatus for ascertaining the cerebral state of a patient, including a state resulting from the administration of a drug, said apparatus comprising:
(a) means for obtaining biopotential signals from the patient, the biopotential signals containing EEG signal data and EMG signal data, the EMG signal data being primarily of a higher frequency than the EEG signal data which is primarily of a lower frequency;
(b) means for analyzing a sample of sequential signal data over a frequency range that is sufficiently wide to include both the EEG and EMG signal data to obtain a measure of the complexity of the signal data; and
(c) means providing the complexity measure as an indicator of the cerebral state of the patient.

### Claim 76 (depends on 75)

The apparatus according to claim 75 wherein said analyzing means is further defined as using a length of EEG signal data and using a EMG signal data sample of shorter length than the EEG signal data sample, and wherein said means updates said indicator a repetition rate determined by the shorter sample length of the EMG signal data to indicate changes in the cerebral state of the patient.

### Claim 77 (depends on 75, 76)

The apparatus according to claim 75 or claim 76 wherein said analyzing means is further defined as analyzing the signal data over a frequency range extending from a frequency of about 0.5 Hz to a frequency which is above 32 Hz.

### Claim 78 (depends on 75, 76)

The apparatus according to claim 75 or claim 76 wherein said analyzing means is further defined as obtaining a measure of the entropy of the signal data.

### Claim 79 (depends on 77)

The apparatus according to claim 77 wherein said analyzing means is further defined as obtaining a measure of the entropy of the signal data.

### Claim 80 (depends on 75, 76)

The apparatus according to claim 75 or claim 76 wherein said analyzing means is further defined as obtaining a Lempel-Ziv complexity measure of the signal data.

### Claim 81 (depends on 75, 76)

The apparatus according to claim 75 or claim 76 further defined as one for ascertaining the hypnotic state of a patient.

### Claim 82 (depends on 75, 76)

The apparatus according to claim 75 or claim 76 wherein said analyzing means further defined as analyzing a sample of the EEG signal data to obtain a complexity measure of the EEG signal data and said providing means is further defined as providing the complexity measure of the EEG signal data as further indicator of the cerebral state of the patient.

### Claim 83 (depends on 82)

The apparatus according to claim 82 further including means for normalizing the further indication obtained from the analysis of the EEG signal data and the EEG-EMG signal data indication so that the further indication and EEG-EMG indication are equal in the absence of EMG signal data.

### Claim 84 (depends on 68, 75)

The apparatus according to claim 68 or claim 75 further defined as including means notch filtering the signal data to remove power line frequency harmonics.

### Claim 85 (depends on 68, 75)

The apparatus according to claim 68 or claim 75 further defined as including means for processing the signal data to detect artifacts.

### Claim 86 (depends on 85)

The apparatus according to claim 85 further defined as including means for filtering the signal data to remove artifacts.
